Final answer:
Third-generation fluoroquinolones are antibiotics used to treat CAP by targeting bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae, working by inhibiting enzymes critical for DNA replication.
Step-by-step explanation:
The 3rd generation fluoroquinolones used to treat community-acquired pneumonia (CAP) typically targets a broad spectrum of bacteria, including key pathogens responsible for CAP. They are known for their efficacy against bacterial strains such as Streptococcus pneumoniae, and Haemophilus influenzae, and atypical bacteria, like Mycoplasma pneumoniae. Fluoroquinolones work by inhibiting bacterial enzymes DNA gyrase and topoisomerase IV, essential for DNA replication and thus bacterial growth. This class of antibiotics has become crucial, especially when other drugs like β-lactams and macrolides face resistance issues. However, it is important to consider individual resistance patterns and potential side effects when prescribing these medications.